Researchers from the U.S. National Institutes of Health (NIH) recently pub­lished what they describe as a "curative blueprint" for myeloma.

The "blueprint" outlines key issues the researchers believe need to be ad­dressed if medical science is to achieve a cure for myeloma.

A crucial question that needs to be answered, the researchers argue, is whether treating "early myeloma" is more advantageous than waiting until the disease has progressed to the symptomatic, or active, stage.

The NIH researchers define "early myeloma" as symptomatic myeloma with limited organ damage, or smol­dering multiple myeloma with …